Respiratory Stimulant Compositions for Post-Ventilator Depression

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Patients experiencing respiratory depression after prolonged ventilator use due to demyelination or atelectasis, which can lead to inadequate ventilation and increased neural respiratory drive, require effective treatment to restore normal breathing patterns.

Innovation Solution

Administering a respiratory stimulant, potentially combined with hydroxychloroquine, antibiotics like azithromycin, antivirals such as amantadine, bronchodilators like albuterol, and lung recruitment maneuvers to treat respiratory depression caused by demyelination or atelectasis.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If a patient undergoes prolonged ventilator therapy, then respiratory support is maintained, but demyelination and atelectasis occur causing respiratory depression

Engineering Contradiction:

Improverespiratory supportVSAvoiddemyelination and atelectasis

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent applies preliminary action by administering respiratory stimulants prophylactically during or immediately after prolonged ventilator therapy to prevent the development of respiratory depression caused by demyelination and atelectasis, rather than waiting for symptoms to manifest

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The patent converts the harmful effects of prolonged ventilation (demyelination and atelectasis) into a treatable condition by using respiratory stimulants that specifically address the neural respiratory drive deficiency caused by these conditions, transforming a complication into a manageable scenario

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

2Strength

If lung compliance decreases due to atelectasis, then greater neural respiratory drive is required, but respiratory depression occurs when additional drive is not achieved

Engineering Contradiction:

Improveneural respiratory driveVSAvoidventilation adequacy

Core Design Contradiction:

StrengthVSReliability

Solution Approach 1:

The patent applies parameter changes by using respiratory stimulants that directly modify the neural respiratory drive parameter, increasing the frequency and/or depth of breathing to compensate for decreased lung compliance and atelectasis without requiring mechanical intervention

Inventive Principle:

Principle #35Parameter changes

3Ease of operation

If respiratory stimulants are administered to treat respiratory depression, then normal respiratory rhythm is restored, but hyperventilation must be avoided

Engineering Contradiction:

Improverespiratory rhythm restorationVSAvoidhyperventilation

Core Design Contradiction:

Ease of operationVSObject-affected harmful factors

Solution Approach 1:

The patent applies feedback by monitoring respiratory parameters (such as tidal volume, respiratory rate, and blood gas levels) to adjust the dosage and administration of respiratory stimulants, ensuring that therapeutic effects are achieved without exceeding the threshold for hyperventilation

Inventive Principle:

Principle #23Feedback

Data Source

PatentUS20250325554A1Methods and pharmaceutical compositions to treat respiratory depression in patients

Publication Date: 2025.10.23 ENALARE THERAPEUTICS INC

AI summary

The present disclosure provides a method of treating respiratory depression in a patient after discontinuation of ventilator therapy comprising administering a respiratory stimulant to a patient in need thereof.